Generate Biomedicines to Participate in November Investor ConferencesGlobeNewsWire · 4 days ago
Banque Pictet & Cie SA Buys New Position in Generate Biomedicines Inc $GENBDefense World · Oct 17, 2026
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGlobeNewsWire · Oct 13, 2026
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGlobeNewsWire · Oct 13, 2026
Generate Biomedicines: The Dosing Interval Is The Moat, Not The AlgorithmSeeking Alpha · Oct 13, 2026
Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB)Defense World · Oct 4, 2026Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy.